Massar Capital Management’s Moderna MRNA Stock Holding History

Massar Capital Management’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-202,674	Closed	-$8.43M	–	145
2024 Q4	$8.43M	Buy	+202,674	New	+$9.69M	9.58%	1

Other funds holding MRNA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Massar Capital Management's MRNA Position: Q1 2025 in Review

Massar Capital Management sold out of Moderna (MRNA) in Q1 2025, closing a stake of 202,674 shares — an estimated $8.43M sold.

Massar Capital Management first reported a position in MRNA in Q4 2024 and held it in 1 quarter. The position peaked at $8.43M in Q4 2024. 694 funds tracked by Wall St. Rank hold MRNA as of Q1 2025.

Massar Capital Management reported no remaining Moderna position as of Q1 2025 after selling out during the quarter.
Massar Capital Management sold 202,674 Moderna shares in Q1 2025, an estimated $8.43M.
Massar Capital Management first reported a position in Moderna in Q4 2024 and held it in 1 quarter.
Massar Capital Management's Moderna position peaked at $8.43M in Q4 2024.
694 funds tracked by Wall St. Rank held Moderna as of Q1 2025.

Based on Massar Capital Management's 13F filing for Q1 2025, filed 15 May 2025.